Progress of local symptoms of superficial vein thrombosis vs. duplex findings

Gorski, Grzegorz; Noszczyk, W; Kostewicz, W; Szopiński, Piotr; Kielar, Maciej; Michalak, Jacek; Marianowska, Agnieszka; Wilkowski, Dariusz

doi:10.1024/0301-1526.33.4.219

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may also be a decisive factor in the presence of clinically difficult differential diagnosis with cellulitis, panniculitis, erythema nodosum, insect bites, and lymphangiitis. 12,19,[47][48][49]…”

Section: Diagnosismentioning

confidence: 99%

Superficial Vein Thrombosis: Risk Factors, Diagnosis, and Treatment

Marchiori¹,

Mosena²,

Prandoni³

2006

Semin Thromb Hemost

View full text Add to dashboard Cite

Superficial vein thrombosis (SVT) is a very common disease even though its incidence has never been assessed properly. Until recently, the literature on this topic has been relatively poor, old, and with numerous methodologic drawbacks, probably because this disease was considered benign and trivial. However, the recent recognition of a frequent association with concomitant venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) and the risk of subsequent VTE complications in patients with isolated SVT has revived interest and has encouraged new clinical research. SVT and VTE share many common predisposing risk factors. Even if varicose veins represent the main cause of SVT, several underlying conditions (e.g., malignancy, thrombophilia, autoimmune diseases) should be sought, especially in idiopathic, migrant, or recurrent SVT of nonvaricose vein patients. The diagnosis is made in a clinical setting but ultrasonography is useful to identify concomitant asymptomatic DVT. Many medical and surgical treatments have been suggested to relieve local symptoms and signs, prevent recurrences, and limit the VTE risk of SVT, but the evidence coming from the limited number of prospective randomized studies does not allow strong recommendations on the optimal treatment of SVT.

show abstract

Section: Diagnosismentioning

confidence: 99%

Superficial Vein Thrombosis: Risk Factors, Diagnosis, and Treatment

Marchiori¹,

Mosena²,

Prandoni³

2006

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Duplex Scan (DS) has become the examination method of choice because of its low cost, effectiveness for diagnosis, and low patient risk. 51,52 Considering the high incidence of DVT combined with the risk of progression of thrombosis and of PE, 53 it is recommended that DM is used to examine all cases of SVT in the lower limbs 52 (Evidence level 2B).…”

Section: Ultrasoundmentioning

confidence: 99%

Diretrizes de conceito, diagnóstico e tratamento da trombose venosa superficial

et al. 2019

View full text Add to dashboard Cite

Resumo A trombose venosa superficial (TVS), também denominada de tromboflebite superficial, caracteriza-se pela formação de trombos dentro de veias superficiais, com suboclusão ou oclusão da luz e reação inflamatória no seu trajeto, sendo mais comum nos membros inferiores. Afeta de 3 a 11% da população geral. O diagnóstico costuma ser clinicamente fácil, mas sua extensão e possíveis complicações tromboembólicas precisam de exames subsidiários para confirmação. A TVS pode estar associada a trombose venosa profunda em 6 a 40% dos casos, a embolia pulmonar assintomática (EP) em 20 a 33%, e a EP sintomática em 2 a 13%. Apesar de sua morbidade e das suas complicações, ainda não existem diretrizes brasileiras para a TVS. Nesta diretriz, foram analisadas as principais dúvidas quanto à definição, terminologia e etiologia da TVS, com recomendações para seu diagnóstico e tratamento.

show abstract

“…When isolated, i.e., without concomitant deep vein thrombosis (DVT) or pulmonary embolism (PE), which is the case in the vast majority of patients, the clinical outcome is usually favorable: pain is reduced by more than half over the first week, and inflammation regresses in 2 to 3 weeks. [13][14][15][16] CALISTO results cannot apply to every patient with SVT. [1] Many patients were excluded from the trial due to restrictive eligibility criteria excluding patients with SVT measuring less than 5 cm in length and patients with a high thromboembolic risk (active cancer, recent history of thromboembolism, SVT located at less than 3 cm of the sapheno-femoral junction (SFJ)) or high hemorrhagic risk and severe renal failure.…”

Section: Definitionmentioning

confidence: 99%

“…[19] The acute episodic character of SVTs distinguishes them from simple variations within the norm. [13,14] 6…”

Section: Definitionmentioning

confidence: 99%